| Literature DB >> 30285881 |
Jennifer Pasquier1,2,3, Fabien Vidal1,2, Jessica Hoarau-Véchot1, Claire Bonneau4, Emile Daraï4, Cyril Touboul5, Arash Rafii6,7,8.
Abstract
BACKGROUND: The mainstay of treatment of advanced ovarian cancer (AOC) involves chemotherapy, and debulking surgery. However, despite optimal surgical procedure and adjuvant chemotherapy, 60% of patients with AOC will relapse within 5 years. Most recurrences occur in the peritoneal cavity, suggesting the existence of occult sanctuaries where ovarian cancer cells (OCC) are protected. In murine models, surgical stress favors tumor growth; however, it has never been established that surgery may affect OCC sensitivity to subsequent chemotherapy. In this study, we investigated how the surgical stress could affect the chemosensitivity of OCC.Entities:
Keywords: Chemoresistance; IL8; Ovarian cancer; Surgery; Tumor microenvironment
Mesh:
Substances:
Year: 2018 PMID: 30285881 PMCID: PMC6171219 DOI: 10.1186/s12967-018-1643-z
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Comparative demographics between chemoresistant and platinium sensitive patients
| Platinium resistant subgroup (n = 16) | Platinium sensitive subgroup (n = 12) | p-value | |
|---|---|---|---|
| Age (years) | 60.4 (± 12.1) | 63.8 (± 6.6) | 0.38 |
| BMI | 24.1 (± 4.6) | 23.8 (± 3.2) | 0.82 |
| CA 125 (U/ml) at baseline | 2600 (± 3098.2) | 1235 (± 1252.0) | 0.16 |
| Histological type | |||
| Serous | 87.5% (n = 14) | 66.7% (n = 8) | 0.58 |
| Undifferentiated | 6.25% (n = 1) | 16.7% (n = 2) | |
| Mucinous | 0 | 8.3% (n = 1) | |
| Endometrioid | 6.25% (n = 1) | 8.3% (n = 1) | |
| FIGO stage | |||
| IIIC | 81.2% (n = 13) | 100% (n = 12) | 0.11 |
| IV | 18.8% (n = 3) | 0 | |
| Count of NAC courses | 4 (3–6) | 3 (3–7) | 0.34 |
| Total count of chemotherapy courses | 7 (3–12) | 6 (3–9) | 0.15 |
| Delay between diagnosis and surgical debulking (months) | 4.3 (± 1.2) | 3.9 (± 1.2) | 0.43 |
| Completeness of cytoreduction scorea | |||
| CC-0 | 68.7% (n = 11) | 83.4% (n = 10) | 0.38 |
| CC-1 | 6.3% (n = 1) | 0 | |
| CC-2 | 18.7% (n = 3) | 8.3% (n = 1) | |
| CC-3 | 6.3% (n = 1) | 8.3% (n = 1) | |
| Mean IL8 expression on tumor sample | 31.3% | 11.0% | 0.004** |
| Duration of surgical procedure (min) | 428 (± 139) | 310 (± 82) | 0.07 |
| Overall survival (months) | 31.9 | 78.9 | < 10−4*** |
BMI body mass index, NAC neoadjuvant chemotherapy
aA CC-0 score indicates a complete disease removal; a CC-1 score indicates that tumor nodules persisting after cytoreduction were < 2.5 mm in diameter; a CC-2 score indicates residual tumor nodules between 2.5 mm and 25 mm in diameter; a CC-3 score indicates residual tumor nodules > 25 mm in diameter or a confluence of unresectable tumor nodules at any site within the abdomen or pelvis
Fig. 1a Schematic representation of the procedure. During a laparotomy performed for benign gynecologic condition, a peritoneal biopsy is done at the incision site (H0) and a second one is done 1 h after the incision (H1). b Phase contrast microscopy imaging. Ovarian cancer cells (APOCC) treated with Taxol (0–20 µM) for 24 h in presence of H0 (middle picture), H1 (right picture) or nothing (left picture). Scale bar: 500 µm. c MTT assay. APOCC were treated with Taxol (0.01–20 µM) in presence of H0 (green), H1 (purple) or nothing (grey). After 48 h a MTT assay was performed. The histogram represents the mean OD MTT. d Cell viability. APOCC untreated (control, top left), treated with Taxol (20 µM) alone (top right) or treated with Taxol (20 µM) in presence of H0 (bottom left) or H1 (bottom right) were stained with calcein-AM. Calcein fluorescence was acquired by flow cytometry. e Proliferation assay. APOCC were plated and counted every 2 days in presence or not of H0 or H1 during 6 days. f Cell cycle analysis. APOCC were treated with H0 or H1 for 48 h and position in cell cycle were evaluated with NIM-DAPI by flow cytometry. The percentage of cells in phase G0/G1 (purple) and in G2/M (blue) is represented on the histogram. g F-actin polymerisation in APOCC. APOCC were grown on glass bottom slides with H0 or H1 and actin cytosqueletton was revealed by a phalloïdin-fluorescein (1 μg/ml) labelling (red). Scale bar 15 μm. h Wound closure assay. Migration ability of APOCC was tested after a scratch in presence of different H0 or H1. The histogram represents the percentage of wound closure after 6, 24 or 48 h. i APOCC plasticity on Matrigel. APOCC were seeded on a 96-wells plate, coated with Matrigel in presence or absence of H0 or H1. Microscopic pictures of cellular networks after H0 and H1 stimulation were taken after 4, 6 and 24 h of culture. Quantitative evaluation of the cellular interconnection are presented on the histogram. The evaluation was made by counting on 10 different fields. The results are expressed as means treated/mean control with standard error. Experiments were performed in triplicate. *p < 0.05, **p < 0.01 or ***p < 0.001
Fig. 2a Cytokine array. Cytokine arrays were performed on H0 and H1 of five patients (numbered 1–5 on the figure). Each column in the cluster graphics represents one sample and each line a cytokine. The intensity ranges from green (less expressed) to red (more expressed). b Pixel density of selected cytokines. The pixel density of the most expressed cytokines in H1 are represented on the histogram normalized with the H0 pixel density. c MTT assay. APOCC were pre-treated for 24 h with human recombinant cytokines (CD54, IL-6, IL-8, Serpin E1, Rantes, C5/C5a or G-CSF) prior to Taxol treatment (20 µM). After 48 h a MTT assay was performed. The histogram represents the mean OD MTT. d Cell viability. APOCC were pre-incubated with H0 or H1 prior Taxol (20 µM) treatment (left panel). APOCC pre-incubated with H0 were also incubated with specific blocking antibodies for IL-6, IL-8, Rantes or G-CSF prior Taxol (20 µM) treatment (right panel). The percentage of live cells (blue), dead cells (red), apoptotic cells (purple) and debris (green) are represented in the histogram on the right
Fig. 3a Nucleus fragmentation. APOCC alone (control), pre-incubated with H1 or pre-incubated with H1+ a blocking antibody for IL-8 (bAB IL-8) were treated with Taxol (20 µM). Confocal microscopy was performed on the cells stained with DAPI. Pictures are representative of the nucleus in the well. Scale bar: 5 µm. b The relative quantification of apoptosis genes was performed by real-time qPCR on APOCC after different treatment (H0, H1, bAB IL-8). Relative transcript levels are represented as the log10 of ratios between the two subpopulations of their 2−ΔΔCp real-time PCR values. c APOCC cells pre-incubated or not with H1 with or without bAB IL-8 for 24 h were treated with Taxol (20 µM). Caspase and cleaved Caspase 3 and 9 were assessed by western blot. Induced apoptosis on APOCC using an anti-Fas receptor (CD95) monoclonal antibody (mAb) was used as a positive control
Fig. 4a Phospho-AKT western blot. APOCC cells pre-incubated or not with H1 with or without bAB IL-8 for 24 h were treated with Taxol (20 µM). Phospho-AKT was assessed by western blot. b Apoptosis assay. APOCC cells pre-incubated or not with H1 with or without an Akt inhibitor (LY294002) for 24 h were treated with Taxol (20 µM). Apoptosis was evaluated by flow cytometry using an apoptosis array. Live cells are represented in green and apoptotic cells in red. c The relative quantification of apoptosis genes was performed by real-time qPCR on APOCC before or after treatment with H1 or H1 + LY294002. Relative transcript levels are represented as the log10 of ratios between the two subpopulations of their 2−ΔΔCp real-time PCR values. d The relative quantification of IL-8 and IL-8 receptor genes was performed by real-time qPCR on APOCC before or after treatment with H1, H1 bAB IL-8 or H1 + LY294002. Relative transcript levels are represented as the log10 of ratios between the two subpopulations of their 2−ΔΔCp real-time PCR values
Comparative demographics according to tumoral expression of IL8
| Study population (n = 32) | High IL8 group (n = 8) | Low IL8 group (n = 24) | p-value | |
|---|---|---|---|---|
| Age (years) | 62.4 (± 10.1) | 61.4 (± 12.6) | 62.8 (± 9.4) | 0.75 |
| BMI | 23.7 (± 3.9) | 24.4 (± 4.5) | 23.7 (± 3.9) | 0.68 |
| CA 125 (U/ml) at baseline | 1878.5 (± 2402.6) | 3615.6 (± 4010.7) | 1299.6 (± 1218.2) | 0.01* |
| Histological type | ||||
| Serous | 81.3% (n = 26) | 87.5% (n = 7) | 79.2% (n = 19) | 0.67 |
| Mucinous | 3.1% (n = 1) | 0 | 4.2% (n = 1) | |
| Endometrioid | 6.2% (n = 2) | 0 | 8.3% (n = 2) | |
| Undifferentiated | 9.4% (n = 3) | 12.5% (n = 1) | 8.3% (n = 2) | |
| FIGO stage | ||||
| IIIC | 87.5% (n = 28) | 75.0% (n = 6) | 91.7% (n = 22) | 0.08 |
| IV | 12.5% (n = 4) | 25.0% (n = 2) | 8.3% (n = 2) | |
| Number of NAC courses | 4 (3–7) | 4 (3–6) | 4 (3–7) | 0.32 |
| Total number of chemotherapy courses | 6 (3–12) | 6 (3–10) | 6 (3–12) | 0.24 |
| Delay between diagnosis and surgery (months) | 3.7 (2.6–9.3) | 3.8 (2.9–7.0) | 3.7 (2.6–9.3) | 0.42 |
| Completeness of cytoreduction scorea | ||||
| CC-0 | 78.1% (n = 25) | 62.5% (n = 5) | 83.3% (n = 20) | 0.22 |
| CC-1 | 3.1% (n = 1) | 0 | 4.2% (n = 1) | |
| CC-2 | 12.5% (n = 4) | 25.0% (n = 2) | 8.3% (n = 2) | |
| CC-3 | 6.3% (n = 2) | 12.5% (n = 1) | 4.2% (n = 1) | |
| Duration of surgical procedure (min) | 389 (± 127) | 360 (± 132) | 401 (± 127) | 0.52 |
| Disease free survival (months) | 29.4 (± 5.1) | 12.2 (± 1.0) | 35.6 (± 6.5) | 0.001** |
| Overall survival (months) | 54.8 (± 6.1) | 32.4 (± 7.3) | 63.3 (± 7.1) | 0.009** |
| Chemoresistance | ||||
| Yes | 57.2% (n = 16) | 100.0% (n = 8) | 40.0% (n = 8) | 0.004** |
| No | 42.8% (n = 12) | 0 | 60.0% (n = 12) | |
BMI body mass index, NAC neoadjuvant chemotherapy
aA CC-0 score indicates a complete disease removal; a CC-1 score indicates that tumor nodules persisting after cytoreduction were < 2.5 mm in diameter; a CC-2 score indicates residual tumor nodules between 2.5 mm and 25 mm in diameter; a CC-3 score indicates residual tumor nodules > 25 mm in diameter or a confluence of unresectable tumor nodules at any site within the abdomen or pelvis